Nicholas Locantore
Nicholas Locantore
Dirección de correo verificada de gsk.com
Título
Citado por
Citado por
Año
Susceptibility to exacerbation in chronic obstructive pulmonary disease
JR Hurst, J Vestbo, A Anzueto, N Locantore, H Müllerova, R Tal-Singer, ...
New England Journal of Medicine 363 (12), 1128-1138, 2010
26932010
Blood eosinophil counts, exacerbations, and response to the addition of inhaled fluticasone furoate to vilanterol in patients with chronic obstructive pulmonary disease: a …
S Pascoe, N Locantore, MT Dransfield, NC Barnes, ID Pavord
The lancet Respiratory medicine 3 (6), 435-442, 2015
5892015
Inflammatory biomarkers improve clinical prediction of mortality in chronic obstructive pulmonary disease
BR Celli, N Locantore, J Yates, R Tal-Singer, BE Miller, P Bakke, ...
American journal of respiratory and critical care medicine 185 (10), 1065-1072, 2012
3992012
Robust principal component analysis for functional data
N Locantore, JS Marron, DG Simpson, N Tripoli, JT Zhang, KL Cohen, ...
Test 8 (1), 1-73, 1999
3531999
Determinants of depression in the ECLIPSE chronic obstructive pulmonary disease cohort
NA Hanania, H Müllerova, NW Locantore, J Vestbo, ML Watkins, ...
American journal of respiratory and critical care medicine 183 (5), 604-611, 2011
3272011
Blood eosinophils and inhaled corticosteroid/long-acting β-2 agonist efficacy in COPD
ID Pavord, S Lettis, N Locantore, S Pascoe, PW Jones, JA Wedzicha, ...
Thorax 71 (2), 118-125, 2016
2992016
Eosinophilic inflammation in COPD: prevalence and clinical characteristics
D Singh, U Kolsum, CE Brightling, N Locantore, A Agusti, R Tal-Singer
European Respiratory Journal 44 (6), 1697-1700, 2014
2762014
Serum surfactant protein D is steroid sensitive and associated with exacerbations of COPD
DA Lomas, EK Silverman, LD Edwards, NW Locantore, BE Miller, ...
European respiratory journal 34 (1), 95-102, 2009
2592009
Hospitalized exacerbations of COPD: risk factors and outcomes in the ECLIPSE cohort
H Müllerova, DJ Maselli, N Locantore, J Vestbo, JR Hurst, JA Wedzicha, ...
Chest 147 (4), 999-1007, 2015
2392015
FULFIL trial: once-daily triple therapy for patients with chronic obstructive pulmonary disease
DA Lipson, H Barnacle, R Birk, N Brealey, N Locantore, DA Lomas, ...
American journal of respiratory and critical care medicine 196 (4), 438-446, 2017
2212017
Genetic loci associated with chronic obstructive pulmonary disease overlap with loci for lung function and pulmonary fibrosis
BD Hobbs, K De Jong, M Lamontagne, Y Bossé, N Shrine, MS Artigas, ...
Nature genetics 49 (3), 426-432, 2017
1902017
Should we view chronic obstructive pulmonary disease differently after ECLIPSE?. A clinical perspective from the study team
J Vestbo, A Agusti, EFM Wouters, P Bakke, PMA Calverley, B Celli, ...
American journal of respiratory and critical care medicine 189 (9), 1022-1030, 2014
1552014
Lessons from ECLIPSE: a review of COPD biomarkers
R Faner, R Tal-Singer, JH Riley, B Celli, J Vestbo, W MacNee, P Bakke, ...
Thorax 69 (7), 666-672, 2014
1312014
Efficacy and safety of an anti–IL-13 mAb in patients with severe asthma: A randomized trial
EH De Boever, C Ashman, AP Cahn, NW Locantore, P Overend, ...
Journal of allergy and clinical immunology 133 (4), 989-996. e4, 2014
1292014
Serum PARC/CCL-18 concentrations and health outcomes in chronic obstructive pulmonary disease
DD Sin, BE Miller, A Duvoix, SFP Man, X Zhang, EK Silverman, ...
American journal of respiratory and critical care medicine 183 (9), 1187-1192, 2011
1152011
Identification of five chronic obstructive pulmonary disease subgroups with different prognoses in the ECLIPSE cohort using cluster analysis
SI Rennard, N Locantore, B Delafont, R Tal-Singer, EK Silverman, ...
Annals of the American Thoracic Society 12 (3), 303-312, 2015
972015
New genetic signals for lung function highlight pathways and chronic obstructive pulmonary disease associations across multiple ancestries
N Shrine, AL Guyatt, AM Erzurumluoglu, VE Jackson, BD Hobbs, ...
Nature genetics 51 (3), 481-493, 2019
782019
A comparison of the efficacy and safety of once-daily fluticasone furoate/vilanterol with twice-daily fluticasone propionate/salmeterol in moderate to very severe COPD
A Agustí, L de Teresa, W De Backer, MT Zvarich, N Locantore, N Barnes, ...
European Respiratory Journal 43 (3), 763-772, 2014
652014
Factors associated with change in exacerbation frequency in COPD
GC Donaldson, H Müllerova, N Locantore, JR Hurst, PMA Calverley, ...
Respiratory research 14 (1), 79, 2013
652013
A phase III randomised controlled trial of single-dose triple therapy in COPD: the IMPACT protocol
SJ Pascoe, DA Lipson, N Locantore, H Barnacle, N Brealey, R Mohindra, ...
European Respiratory Journal 48 (2), 320-330, 2016
632016
El sistema no puede realizar la operación en estos momentos. Inténtalo de nuevo más tarde.
Artículos 1–20